Literature DB >> 30772494

Juvenile polyautoimmunity in a rheumatology setting.

Clara Malagón1, Maria Del Pilar Gomez2, Catalina Mosquera3, Camilo Vargas4, Tatiana Gonzalez5, Cristine Arango6, Lorena Martin7, Pilar Perez8, Laura Amaya-Uribe9, Nicolas Molano-Gonzalez9, Juan-Manuel Anaya10.   

Abstract

Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single patient. The current study aimed to describe the main characteristics of juvenile PolyA in a pediatric rheumatology setting and analyze the chronological aspects, index cases, familial autoimmunity, and clustering pattern. This was a cross-sectional and multicenter study in which 313 children with overt PolyA were included. Patients were systematically interviewed and their medical records reviewed using a questionnaire that sought information about demographic, clinical, immunological, and familial characteristics. A hierarchical cluster analysis was done to determine similarities between autoimmune diseases based on PolyA. PolyA occurred simultaneously in 138 (44%) patients. Multiple autoimmune syndrome was observed in 62 (19.8%) patients. There were 25 index diseases of which, systemic lupus erythematosus (SLE, n = 134, 42.8%), juvenile idiopathic arthritis (JIA, n = 40, 12.7%), Hashimoto's thyroiditis (HT, n = 24, 7.66%), immune thrombocytopenic purpura (ITP n = 20, 6.39%), antiphospholipid syndrome (APS, n = 15, 4.79%), and vitiligo (VIT, n = 15, 4.79%) were the most frequent and represented 79.23% of the total number of patients. Familial autoimmunity influenced PolyA. A high aggregation of autoimmunity was observed (λr = 3.5). Three main clusters were identified, of which SLE and APS were the most similar pair of diseases (based on the Jaccard index) followed by HT and JIA, which were related to ITP and Sjögren's syndrome. The third cluster was composed of localized scleroderma and VIT. Our findings may assist physicians to make an early diagnosis of this frequent condition. Pediatric patients with ADs should be systematically assessed for PolyA.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Autoimmune diseases; Autoimmune tautology; Juvenile idiopathic arthritis; Juvenile patients; Polyautoimmunity; Systemic lupus erythematous

Mesh:

Year:  2019        PMID: 30772494     DOI: 10.1016/j.autrev.2018.11.006

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

1.  Clinical patterns and risk factors in scleritis: a multicentric study in Colombia.

Authors:  Alejandra de-la-Torre; Mariana Cabrera-Pérez; Claudia Durán; Sandra García; Miguel Cuevas; Néstor Carreño; Carlos M Rangel; Diana Isabel Pachón-Suárez; María Alejandra Martínez-Ceballos; María Elisa Mejía; Alejandra Gómez-Rocha; Camilo Andrés Gómez-Durán; Yanny Pérez; Juliana Reyes-Guanes; Carlos Cifuentes-González; William Rojas-Carabali
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-07       Impact factor: 3.117

Review 2.  Association of juvenile idiopathic arthritis and morphea: a case series.

Authors:  Teresa Giani; Anna Madera; Rolando Cimaz
Journal:  Clin Rheumatol       Date:  2019-12-14       Impact factor: 2.980

3.  Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Bin Huang; Chen Chen; Sheila T Angeles-Han; Teresa A Simon; Hermine I Brunner
Journal:  RMD Open       Date:  2021-03

4.  Intermediate Uveitis Etiology, Complications, Treatment, and Outcomes in a Colombian Uveitis Referral Center.

Authors:  William Rojas-Carabali; Juliana Reyes-Guanes; Valeria Villabona-Martinez; Maria Alejandra Fonseca-Mora; Alejandra de-la-Torre
Journal:  Clin Ophthalmol       Date:  2021-06-21

5.  Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy.

Authors:  Lauren M Pachman; Brian E Nolan; Deidre DeRanieri; Amer M Khojah
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-02-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.